EGYPT Osteoporosis market analysis 2010
-
Upload
walid-saafan -
Category
Health & Medicine
-
view
1.155 -
download
1
description
Transcript of EGYPT Osteoporosis market analysis 2010
Osteoporosis market opportunities
Cairo
Prepared by: Walid Saafan
Topics
Summary
Market Overview
Medical analysis
Promotional analysis
Cost analysis for leading brands
Summary
The Osteoporosis market size:
– Sales: 10.2 Mio US$ in representing 0.4% of the total market GR%
+9.9%, and CAGR 10.7% vs total market GR% of +16.4% and
CAGR +18.3%.
– Units: 559K packs, GR% +10.4% and CAGR +7.4% vs total
market GR% +11.7% and CAGR +9.7%.
Osteoporosis market is derived by Multinational corporations
(Novartis, MSD, Servier, and Sanofi Aventis) represent 85% of the
market.
The osteoporosis is not reimbursed in the MOH and the sales are
driven from the private market (out pocket).
The market is derived by Bisphosphonate class representing 54% of
the total market followed be Calcitonins representing 32%, both
classes represent 86% of the market.
Source: IMS Y09
Summary – cont.,
The MKT is consisting of 3 trends
– Bisphosphonate: divided to Alendronate group mainly Fosavance/
Fosamax from MSD with 8 generics, Residronate group mainly
Actonel from Sanofie Aventis with two generic.
– Calcitonin: the oldest trend led by Miacalcic launched in 1986
– Raloxifen: leading the group Evista from Lilly with 4 generics.
The main segment prescribing antiresorptive for osteoporosis are the
ORTH with 76% Rx share and GR of +11%.
Source: IMS Y09
Market overview – leading classes
Market segmentation
Source: IMS Y09, values in US$
Market overview – leading classes cont.,
Leading brands per classLeading corporate per class
Source: IMS Y09, values in US$
Market overview – market development
Source: IMS Y09, values in K.US$
Total pharma.
Market GR%+19.5% +19.7% +18.9% +16.4%
Market overview – Leading corporate performance
Source: IMS Y09, values in US$
Market overview – Leading brands performance
Source: IMS Y09, values in US$
Medical analysis - Source of RXs
The osteoporosis Rx are mainly generated from ORTH doctors contributing with 75% of all antiresorptive Rx.
Other specialties show minor contribution with a growing potential for the GP segment.
The market is showing low level of stay on therapy for most of brands with an average of 1.8 Pack/Rx for Miacalcic, 1.6 for Protelos and 2 for Actonel and Fosavance.
Source: IMS MAT Q4/09
Medical analysis - Source of RXs
Leading brands per specialty Leading brand source of RXs
Source: IMS MAT Q4/09
Promotional analysis - Target specialties
ORTHO is the main target for details
acquiring 68% of the total details.
New shift from ORTHO towards IM in
Y09.
Source: IMS MAT Q4/09
Promotional analysis - Leading corp. targeting
Corporate target classesLeading corporate per class
Source: IMS MAT Q4/09
Promotional analysis - Share of voice - ORTHO
Novartis has the highest SoV among ORTHO of 25%
(Miacalcic 16% with GR% +41%& ACLASTA +9% with
GR% +22%) with increased focus on IM.
PROTELOS has the highest SoV of 22% with GR% +29%
Source: IMS MAT Q4/09
Promotional analysis - Detail SoV analysis
Leading brands per specialty Brand target classes
Source: IMS MAT Q4/09
Cost analysis for main brands
Source: IMS, Prices in EGP
Thank you
Leading brands per class
Sales US$ CAGR GR%
Osteop.MKT. 10,207,855 10.7 9.9
M05B3 BISPHOSPH 5,498,920 9.9 10.6
FOSAVANCE/FOSAMAX 1,884,977 1.9 (0.3)
ACTONEL 1,229,611 -6.9 (11.6)
ACLASTA 1,139,665 --- 72.4
H04A0 CALCITONINS 3,224,716 4.6 7.2
MIACALCIC/PLUS 3,170,595 4.1 10.6
M05B9 CALCIUM REGULAT 1,341,167 88.6 20.3
PROTELOS 1,293,199 107.7 21.0
G03J0 SERMS 109,414 -30 (34.1)
Leading specialties – RXs
ORTHO., 237,080, 76%
G.P., 39,939, 13%
GYN, 18,075, 6%
Total Others (6) , 14,390,
5%
Y09 Projected RXs
MonthlyTreatment
cost
Yearly treatment
cost
Leading brands
MIACALCIC 367 4,405
PROTELOS 269 3,233
ACTONEL 233 2,802
ACLASTA 1,860
FOZAMAX/FOSAVANCE 217 2,607
SOT PSP
Osteoprosis market
MIACALCIC 17 316
PROTELOS 23 124
ACTONEL 26 107
ACLASTA 64 1,860
FOZAMAX/FOSAVANCE 31 100
NB: brand prices calculated based on the weighted average of its SKU’s public
sales price times the units sales
-
50
100
150
200
250
300
350
400
450
- 10 20 30 40 50 60 70 80
Pri
ce
pe
r m
on
th
Stay on therapy
Chart Title
MIACALCIC
PROTELOS
ACTONEL